Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar;97(3):511-5.   PMCID: PMC5485922
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA, Mick R, Emerson SG, Zhang Y, Vonderheide RH, Porter DL, Reshef R. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood. 2017 Feb 16;129(7):906-16.   PMCID: PMC5314813
Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J, Smith T, Sprod LK, Miller SM. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol. 2017 Jul;3(7):961-8.   PMCID: PMC5557289
Narsinh KH, Van Buskirk M, Kennedy AS, Suhail M, Alsaikhan N, Hoh CK, Thurston K, Minocha J, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG, Sharma NK, Wang EA, Rose SC. Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization. Radiology. 2017 Jan;282(1):281-8.   PMCID: PMC5207118
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England journal of medicine. 2017 Aug 17;377(7):644-57.
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Qin X, Li Y, Sun N, Wang H, Zhang Y, Wang J, Li J, Xu X, Liang M, Nie J, Wang B, Cheng X, Li N, Sun Y, Zhao L, Wang X, Hou FF, Huo Y. Elevated Homocysteine Concentrations Decrease the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors in Hypertensive Patients. Arteriosclerosis, thrombosis, and vascular biology. 2017 Jan;37(1):166-72.
Sato T, Issa JJ, Kropf P. DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor perspectives in medicine. 2017 May;7(5).   PMCID: PMC5411681
Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical therapeutics. 2017 Aug;39(8):1600-17.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-501.
Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer prevention research (Philadelphia, Pa). 2017 Jun;10(6):345-54.   PMCID: PMC5758862
Xu MJ, Chu C, Rubin S, Lin LL. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. Am J Clin Oncol. 2017 Dec;40(6):598-604.   PMCID: PMC4733581
Alvarez P, Jensen LE. Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner. Mediators of inflammation. 2016 Jan;2016:6756138.   PMCID: PMC5183767
Arvold ND, Pinnell NE, Mahadevan A, Connelly S, Silverman R, Weiss SE, Kelly PJ, Alexander BM. Steroid and anticonvulsant prophylaxis for stereotactic radiosurgery: Large variation in physician recommendations. Practical radiation oncology. 2016 Jul;6(4):e89-96.
Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer [comment]. The New England journal of medicine. 2016 Feb 04;374(5):493-4.   PMCID: NA
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213-24.   PMCID: PMC5379654
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Muschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.   PMCID: PMC4850868
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use drug therapy Male Female Middle Aged Aged pathology drug effects adverse effects Treatment Outcome Antineoplastic Agents Adult mortality blood administration & dosage Disease-Free Survival complications prevention & control methods Survival Rate radiotherapy Antineoplastic Combined Chemotherapy Protocols etiology chemically induced analysis Adenocarcinoma statistics & numerical data Retrospective Studies Monoclonal Antibodies-Humanized analogs & derivatives 80 and over Aged Fatigue Intravenous Infusions Time Factors Kaplan-Meier Estimate Mice diagnostic imaging Ki-67 Antigen immunology pharmacology Prognosis Taxoids genetics Tumor Biomarkers chemistry Androgen Antagonists United States metabolism Drug Administration Schedule Prostate-Specific Antigen therapy Prostatic Neoplasms antagonists & inhibitors Colorectal Neoplasms Neoplasms Hormonal Antineoplastic Agents Neoplasm Grading Neoplasm Staging Combined Modality Therapy Diarrhea Response Evaluation Criteria in Solid Tumors physiopathology Risk ROC Curve Tumor Microenvironment Ovarian Neoplasms Apoptosis Anticoagulants CCR5 Receptors Bone Neoplasms SCID Mice C-Type Lectins monoclonal Up-Regulation X-Ray Computed Tomography Lung Neoplasms bcl-2-Associated X Protein Hypoglycemic Agents Folic Acid Exercise Therapy Clear Cell Adenocarcinoma Guanylyl Cyclase C Agonists Neoplastic Stem Cells Proto-Oncogene Proteins c-abl Interleukin-1 Type I Receptors Experimental Leukemia Cyclooxygenase 2 China Maximum Tolerated Dose Surveys and Questionnaires antihypertensive responses Endometrioid Carcinoma Chemoradiotherapy epidemiology Cyclic GMP Glucocorticoids Survival Analysis Targeted therapy Hypotension Canagliflozin Soft Tissue Neoplasms CA-19-9 Antigen Camptothecin Disease Progression surgery Interleukin-1 Dextroamphetamine Enterotoxin Receptors Area Under Curve Glomerular Filtration Rate Microfilament Proteins Pancreatitis-Associated Proteins Local Neoplasm Recurrence Fallopian Tube Neoplasms Dose Fractionation Infliximab Non-Small-Cell Lung Carcinoma Clinical Trials as Topic Natriuretic Peptides use Oxidative Stress Therapeutic Embolization Magnetic Resonance Imaging Salvage Therapy infliximab Pancreatic Neoplasms Hematopoietic Stem Cell Transplantation Colon Rectum Hospitalization Cellular Immunity Animal Disease Models Pyridazines Sarcoma Proto-Oncogene Proteins c-bcl-2 Young Adult Yttrium Radioisotopes Foot Steroids Follow-Up Studies Paclitaxel DNA Demethylation Conformal Radiotherapy Prospective Studies Enoxaparin antibodies Imidazoles Phosphoproteins homocysteine concentrations therapeutic
Last updated on Wednesday, February 05, 2020